Cargando…
Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes
Y-box binding protein-1 (YB-1), involved in cancer progression and chemoradiation resistance, is overexpressed in not only cancer cells but also tumor blood vessels. In this study, we investigated the potential value of amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides (ASOs) tar...
Autores principales: | Setoguchi, Kiyoko, Cui, Lin, Hachisuka, Nobutaka, Obchoei, Sumalee, Shinkai, Kentaro, Hyodo, Fuminori, Kato, Kiyoko, Wada, Fumito, Yamamoto, Tsuyoshi, Harada-Shiba, Mariko, Obika, Satoshi, Nakano, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633255/ https://www.ncbi.nlm.nih.gov/pubmed/29246296 http://dx.doi.org/10.1016/j.omtn.2017.09.004 |
Ejemplares similares
-
Superior Silencing by 2′,4′-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2′,4′-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2012) -
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2021) -
Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides
por: Wada, Fumito, et al.
Publicado: (2021) -
Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022) -
Development of Antisense Drugs for Dyslipidemia
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2016)